Ventricular Assist Devices Market Size Share, Trend Analysis and Growth Forecast till 2028

Mechanical circulatory support (MCS) devices, also known as ventricular assist devices, are implantable mechanical pumps that help pump blood from the lower chambers of the heart to the rest of the body.

Over the forecast period, technological advances in the production of miniature devices with advanced features such as infection control technology are expected to fuel the ventricular assist device market growth. Additionally, positive outcomes such as increased system survival, longevity, durability, and versatility are expected to increase product use.

Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-61094?utm_source=hp&utm_medium=openpr&utm_campaign=hp

According to the Scientific Registry of Transplant Recipients (SRTR) and the Organ Procurement and Transplantation Network (OPTN), approximately 2,431 heart transplants were performed in 2014, with 3,986 people on the waiting list as of February 2015.

Patients with end-stage heart failure who do not have access to a heart donor may benefit from ventricular assist devices, which include a variety of life-saving therapies. There are many ventricular assist devices on the market today; however, many barriers and limiting factors, such as high cost and health risk, have an effect on the devices' adoption rate. End-stage heart failure affects nearly 6 million Americans per year and puts a major financial burden on many countries' healthcare systems. Despite many advancements in healthcare therapies, it is estimated that one million people will develop heart failure, which has a high mortality rate. Left ventricular assist devices have progressed from bridge-to-transplant treatment to destination therapy for patients with advanced heart failure in recent years.

Get ToC for the overview of the premium report: https://www.quincemarketinsights.com/request-toc-61094?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Growth Drivers that Support the Global Ventricular Assist Devices:

• Left ventricular assist devices (LVADs) became the most common product category in 2019, owing to the high number of LVAD implantations reported among patients. In addition, a growing number of patients with end-stage heart failure and a lack of therapeutic options are expected to propel the VAD market forward.

• Implantable devices had the largest market share in 2019, and this trend is projected to continue over the forecast period. Patients who are not eligible for a heart transplant are gradually seeking long-term care options, which is expected to drive the segment's revenue generation.

• North America led the market in 2019. Over the forecast period, demand for ventricular assist devices such as bridge-to-transplant, bridge-to-recovery, and destination therapies is expected to be driven by the presence of well-established reimbursement policies and increasing knowledge. The United States is home to the bulk of the world's obese population, which is one of the main contributors to the increase of cardiovascular disease.

• During the forecast era, Asia Pacific is projected to be the fastest growing regional market, with the highest CAGR. The rising prevalence of cardiovascular disease, which leads to stroke, heart failure, and other end-stage cardiovascular diseases, as well as the industry's ever-improving infrastructure, are accelerating the industry's growth.

Speak to analyst before buying this report: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-61094?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Major companies functioning in the global Ventricular Assist Devices are Abbott Laboratories (St. Jude Medical, Inc.), Asahi Kasei Corporation (Evaheart Medical U.S.A., Inc.), Berlin Heart GmbH, CardiacAssist Technologies, Calon Cardio-Technology Ltd., Jarvik Heart, Inc., ReliantHeart, Inc., Medtronic plc, Terumo Medical Corporation.

Market Segmentation:
By Product:
• Left Ventricular Assist Device [LVAD]
• Right Ventricular Assist Device [RVAD]
• Biventricular Assist Device [BIVAD]

By Application:
• Bridge-to-transplant [BTT] Therapy
• Destination Therapy
• Bridge-to-recovery [BTR] Therapy
• Bridge-to-candidacy [BTC] Therapy

By Design:
• Transcutaneous Ventricular Assist Device
• Implantable Ventricular Assist Device

By Region:
• North America
◦ North America, by Country
▪ US
▪ Canada
▪ Mexico
◦ North America, by Product
◦ North America, by Application
◦ North America, by Design
• Western Europe
◦ Western Europe, by Country
▪ Germany
▪ UK
▪ France
▪ Italy
▪ Spain
▪ The Netherlands
▪ Rest of Western Europe
◦ Western Europe, by Product
◦ Western Europe, by Application
◦ Western Europe, by Design
• Asia Pacific
◦ Asia Pacific, by Country
▪ China
▪ India
▪ Japan
▪ South Korea
▪ Australia
▪ Indonesia
▪ Rest of Asia Pacific
◦ Asia Pacific, by Product
◦ Asia Pacific, by Application
◦ Asia Pacific, by Design
• Eastern Europe
◦ Eastern Europe, by Country
▪ Russia
▪ Turkey
▪ Rest of Eastern Europe
◦ Eastern Europe, by Product
◦ Eastern Europe, by Application
◦ Eastern Europe, by Design
• Middle East
◦ Middle East, by Country
▪ UAE
▪ Saudi Arabia
▪ Qatar
▪ Iran
▪ Rest of Middle East
◦ Middle East, by Product
◦ Middle East, by Application
◦ Middle East, by Design
• Rest of the World
◦ Rest of the World, by Country
▪ South America
▪ Africa
◦ Rest of the World, by Product
◦ Rest of the World, by Application
◦ Rest of the World, by Design

Contact:
Quince Market Insights
Office No- A109
Pune, Maharashtra 411028
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com

ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.